AP NEWS

Drafting and Negotiating Clinical Trial Agreements: 1-Day Programme (London, United Kingdom - May 14, 2019) - ResearchAndMarkets.com

December 7, 2018

DUBLIN--(BUSINESS WIRE)--Dec 7, 2018--The “Drafting and Negotiating Clinical Trial Agreements” conference has been added to ResearchAndMarkets.com’s offering.

Clinical trial agreements are one of the most important agreements in the pharma industry as no research can start without the right agreement in place between sponsor and host organisation. They provide a contract which manages the relationship and responsibilities of both parties, and provide for the allocation of risk, obligations, the protection of academia, terms of collaboration, IP rights and much more.

This intensive one-day programme, delivered by experts in the field, will provide you with a full understanding of the importance of CTAs. It will describe how the regulatory environment affects them and explain the typical clauses which make up a CTA and what the key differences are between European and the US. By the end of this seminar you will be confident in spotting and addressing issues which arise when negotiating and drafting clinical trial agreements.

Agenda

Overview of the legal/policy landscape as it affects the terms of CTAs

What is a clinical trial? EU regulatory framework: What are the key regulatory considerations relevant to conducting a clinical trial? Introduction to the parties to the CTA and key roles and responsibilities Policy issues in public hospitals, e.g. UK NHS approval Other ethical/legal issues Standard contracts, e.g. NHS standard CTA Implications of Brexit

CASE STUDY

Negotiating and drafting CTAs

Overview of issues that frequently come up in the negotiation/drafting of CTAs Introduction to case study Discussion of case study DefinitionsIntellectual property and publication provisionsUse of data generated during the trialData protection, medical records, freedom of information, etc

CASE STUDY

Negotiating and drafting CTAs - Continued discussion of case study:

Manufacture of the investigational medicinal product Warranties and indemnities Liabilities and insurance requirements Termination and its consequences

Additional considerations

Introduction to differences between US, UK and Continental European legal systems and how they may affect contract drafting Unlicensed product vs off-label use First-in-man studies Investigator initiated studies Compliance and anti-corruption issues

PRACTICAL EXERCISE - Negotiation

For more information about this conference visit https://www.researchandmarkets.com/research/3jthn4/drafting_and?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181207005329/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/07/2018 10:45 AM/DISC: 12/07/2018 10:45 AM

http://www.businesswire.com/news/home/20181207005329/en

AP RADIO
Update hourly